ARTICLE | Clinical News

Millennium preclinical data

December 11, 2000 8:00 AM UTC

MLNM researchers said that doses of 0.01-0.1 ?M LDP-341 inhibited proliferation and induced apoptosis in human multiple myeloma cell lines as well as cells isolated from multiple myeloma patients resistant to conventional therapies. The researchers suggested that the compound acts directly on myeloma cells and alters cell signaling and cytokine secretion in bone marrow to inhibit tumor cell growth, induce apoptosis and overcome drug resistance. Data were presented at the American Society of Hematology meeting in San Francisco. ...